Stocks to Benefit From Pandemic Pet Boom

These companies are collecting on a hundred-billion dollar industry

Vikram Barhat 21 July, 2021 | 9:07AM
Facebook Twitter LinkedIn

Dog and cat

Long and lonely lockdowns during the global Covid-19 pandemic forced people to make some adjustments to cope with the stress of life in isolation. In particular, the need for a companion led many people to adopt pets, causing a pet boom in 2020.

According to an American Pet Products Association (APPA) report, about 67% of US households have pets, which equates to 84.9 million homes. The report says Americans spent more than $103 billion on pets in 2020, a figure that’s estimated to climb to more than $109 billion in 2021. Globally, the pet care industry is expected to grow by over 40% to reach from $190 billion in 2018 to $270 billion in 2025.

The ongoing surge in pet ownership is expected to continue as more people skip bustling big cities, opting for a quieter life in the suburbs. The trend could create secular growth winds for the following companies in the pet care industry whose fortunes flourish when pet ownership accelerates. 

 IDEXX Laboratories Inc 

 

Ticker

IDXX

 

Current yield:

-

 

Forward P/E:

80.65

 

Price

$659.54

 

Fair value:

$301

 

Value

119% Premium

 

Moat

Narrow

 

Moat Trend

Positive

 

Star rating

*

Data as of July 13, 2021

Animal care firm Idexx Laboratories (IDXX) primarily develops, makes, and sells products, equipment, and services for pets and livestock. It also provides diagnostic and information systems for veterinary, food, and water testing applications. It derives about 38% of its revenue from outside the US.

Idexx has consistently ramped up its scale and reach in the veterinary diagnostic business to carve a narrow moat. The firm is well-positioned to benefit from the higher pet ownership and spending trends. “Pet ownership continues to grow, with 67% of US households owning pets in 2020 compared with 56% in 1988,” says Morningstar equity report, pointing out that pet owners’ spending on animal products and services has more than tripled since 1994.

The company has carved out a strong position in single-use test kits for in-office use. Idexx’s dominance in this space is underpinned by an impressively wide range of companion animal diagnostic tests delivered in many forms. “These premium-priced, high-margin products offer the convenience of results in less than 10 minutes,” the report says.

The company also boasts a leadership position in off-site lab testing and in-hospital analysers, areas that have historically seen robust growth. “Its focus on developing and broadening its menu of tests makes Idexx more of a one-stop shop for animal hospitals,” says Morningstar equity analyst Debbie S. Wang, who recently boosted the stock’s fair value from $270 to $301, prompted by companion animal segment growth in 2021.

The firm is now aiming to replicate its US success in other developed markets. Wang anticipates “many years of growth ahead [spurred by] rising incomes in emerging markets.” 

 Tractor Supply Co 

 

Ticker

TSCO

 

Current yield:

1.11%

 

Forward P/E:

27.55

 

Price

$186.78

 

Fair value:

$130

 

Value

44% Premium

 

Moat

Narrow

 

Moat Trend

Stable

 

Star rating

*

Data as of July 13, 2021

Tractor Supply (TSCO) is the largest consumer farm specialty retailer in the US with an expected $12 billion in sales in 2021. The firm caters to recreational farmers and ranchers through 1,943 stores in 49 states and 184 Petsense stores. In 2020, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).

“Tractor Supply's generally resilient consumer base allows for more consistent revenue growth through both expanded footprint and category exposure,” says a Morningstar equity report.

The company’s store bases grew 29% to about 1,920 locations (around 2,100 including Petsense), over the prior five-year-period ending in 2020, helping to expand sales. By 2030, Tractor Supply’s store count is forecast to reach 2,800 stores, with Petsense accounting for about 280 locations.

“The niche product offerings place Tractor Supply in a unique position, insulated from peers that focus on one segment of the market,” says Morningstar equity analyst Jaime Katz, noting that the firm’s breadth across product categories provides a one-stop solution for those looking to fill multiple needs across outdoor categories.

Tractor Supply has reached critical mass in its consumer segment, paving the way for consistent profit and margin expansion, asserts Katz, who recently upped the stock’s fair value from $120 to $130, prompted by the first-quarter revenue growth of 43% and same-store sales of 39%, “as the firm continues to benefit from its focus on the socially distant outdoor lifestyle as well as the boom in pet adoptions". 

 Zoetis 

 

Ticker

ZTS

 

Current yield:

0.50%

 

Forward P/E:

44.44

 

Price

$199.31

 

Fair value:

$142

 

Value

40% premium

 

Moat

Wide

 

Moat Trend

Stable

 

Star rating

*

Data as of July 14, 2021

Zoetis (ZTS) sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. Production animals (cattle, pigs, and poultry) make up nearly half of total revenue, while companion animal (dogs, horses, cats) products earn the other half. 

With the largest market share in the industry, Zoetis is the undisputed leader in the global animal health industry. “Zoetis has set itself apart based on its impressive innovation that shows up across its product portfolio, including a number of drugs for specific pet ailments such as separation anxiety,” says a Morningstar equity report.

The firm is also pushing to expand its presence into every segment of animal-related health market, including aquaculture and pet diagnostics. “The animal health industry had long been largely ignored because these businesses were buried within larger human health companies, but no longer,” says Wang.

Unlike the human health industry, animal health industry isn’t constrained by pressure to use generic products and to keep prices low. “Animal health products are purchased by a fragmented group of protein producers, veterinarians, and pet owners, allowing very little bargaining power over the highly concentrated animal health firms,” argues Wang, who recently raised the stock’s fair value from $125 to $142, implying the firm “has benefited from a bump in pet adoptions during the pandemic, and from pet owners noticing pet health issues as they spend more time at home".

Wang expects Zoetis to grow slightly faster than the industry and maintain above-average margins due to its scale and its shift toward the faster-growing companion animal segment.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
IDEXX Laboratories Inc696.85 USD1.44Rating
Tractor Supply Co184.04 USD-0.17Rating
Zoetis Inc Class A203.65 USD0.88Rating

About Author

Vikram Barhat  is a Toronto-based financial writer specialising in investing, stock markets, personal finance and other areas of the financial services industry. 

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement